Kelly Knupp, MD: Increasing Patient Curiosity About CBD in Epilepsy
The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado discussed the popularity of cannabidiol from coverage in the media, and how she sees its use—and the understanding of it—evolving in the coming years.
“There’s been so much media about [CBD]. For families who are living with epilepsy, their cousins, aunts and uncles, and the friends down the street—everybody is talking about it. They say, ‘I saw this in the media,’ and ‘have you tried it?’. So, families do ask about it.”
For Kelly Knupp, MD, pediatric neurologist and epilepsy specialist, Children’s Hospital Colorado, the most important work with cannabidiol (CBD) still remains to be done. She told NeurologyLive that while patient interest has been increasing with the recent approval of Epidiolex (GW Pharmaceuticals) for Lennox-Gastaut and Dravet syndromes, the need for data regarding its long-term safety profile and etiology-specific effects have never been higher.
As much as the Lennox-Gastaut and Dravet clinical trials improved the clinical understanding of CBD, physicians still do not completely understand why specific subgroups of patients respond to CBD and others do not. Meanwhile, with media coverage increasing and its availability skyrocketing, patients require more education than ever—and are requesting it.
At the
For more coverage of IEC 2019,
REFERENCES
Knupp K. Cannabinoids. Presented at: 2019 International Epilepsy Congress. June 22-26, 2019; Bangkok, Thailand.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
